Navigation Links
AEterna Zentaris: Article on Phase 2 Trial with Cetrorelix in BPH to be Published in European Urology Journal
Date:5/13/2008

etrorelix

Cetrorelix is part of AEterna Zentaris' LHRH antagonist therapeutic approach that has demonstrated in Phase 2 studies to provide fast and long-lasting relief of BPH symptoms while being well tolerated, with a low incidence of sexual side effects. Cetrorelix peptide-based drugs were developed by the Company in cooperation with Nobel Prize winner Prof. Andrew Schally, currently of the U.S. Veterans Administration in Miami.

Cetrorelix acetate is marketed under the brand name Cetrotide(R), the first LHRH antagonist approved for therapeutic use as part of in vitro fertilization programs (controlled ovarian stimulation/assisted reproductive technologies) in Europe, the U.S. and Japan. It was launched on the market through Serono (now Merck Serono) in the United States, Europe and in several other countries, as well as in Japan through Shionogi.

About the Cetrorelix Phase 3 Program in BPH

Cetrorelix pamoate is being studied in three Phase 3 trials which will include approximately 1,500 men with symptomatic BPH in the United States, Canada and Europe. One Phase 3 efficacy trial, primarily in the United States and Canada and with additional sites in Europe, involves approximately 600 patients (which are fully enrolled) and is being led by Herbert Lepor, M.D., Professor and Martin Spatz Chairman of Urology, New York University School of Medicine, New York. In the trial, patients enter a no-treatment run-in observation period to confirm severity and stability of voiding symptoms based on the International Prostate Symptom Score (I-PSS). Patients are then randomly allocated to cetrorelix or placebo in a double-blind fashion. Patients are administered cetrorelix by intra-muscular (IM) injection at Week 0, 2, 26 and 28 and are followed up to Week 52. Then, in an open-label extension, patients will receive cetrorelix by IM injection at Week 52, 54, 78 and 80 will be followed up to Week 90.

A second, similarly designed ongoing multi-cent
'/>"/>

SOURCE AETERNA ZENTARIS INC.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. AEterna Zentaris completes management team with the appointment of Chief Medical Officer
2. AEterna Zentaris to Present at Upcoming UBS Global Life Sciences Conference in New York
3. AEterna Zentaris Announces Outcome of Managements Strategic Review
4. AEterna Zentaris to Further Develop Three Follow-up Multi-targeted Cytotoxic Candidates to AEZS-112 as Potential Novel Cancer Treatment
5. AEterna Zentaris Reports First Patients Treated with Anti-Cancer Compound AEZS-108 in Phase 2 Trial in Ovarian and Endometrial Cancers
6. AEterna Zentaris to Present at the Upcoming Roth Capital Partners 20th Annual OC Growth Stock Conference in Dana Point, California
7. Aeterna Zentaris to Announce Fourth Quarter and Full-Year 2007 Financial and Operating Results on March 5, 2008
8. AEterna Zentaris Announces the Departure of SVP, Administrative and Legal Affairs
9. AEterna Zentaris and Paladin Labs Announce Sale and Purchase of Miltefosine Rights
10. Aeterna Zentaris Reports Fourth Quarter and Full-Year 2007 Financial and Operating Results
11. Aeterna Zentaris Begins Second Phase 3 Trial of Cetrorelix for Benign Prostatic Hyperplasia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/30/2014)... October 29, 2014 Global polyvinyl chloride ... world economic crisis during 2008-2009, especially in North America ... and currently is keeping to a growing trend. , ... is utilized in the construction segment. In 2013, the ... profiles, tubing, sheets and rigid film. Moreover, the PVC ...
(Date:10/30/2014)... 30, 2014 James Sherley says he has ... tissue stem cell technology since his days as a principal ... in the late 1990’s. Sherley founded the ASCTC as ... holds all the intellectual property developed in Sherley’s research over ... Massachusetts Institute of Technology (MIT), and more recently as a ...
(Date:10/30/2014)... Calif. , Oct. 30, 2014 Isis Pharmaceuticals, ... therapeutics, today announced that management will present a company overview ... at 8:30 a.m. ET in Boston, MA. ... be available on the "Investors & Media" section of the ... on the Isis website within 48 hours and will be ...
(Date:10/27/2014)... Cary, North Carolina (PRWEB) October 27, 2014 ... was invited earlier this month to sit down with Bryan ... Spencer from RPG Solutions to discuss talent in the Research ... the topics that were highlighted at the roundtable ... in the Triangle, the significance of work/life balance and the ...
Breaking Biology Technology:Global Polyvinyl Chloride Demand Is on Upward Trend Now, Says Merchant Research & Consulting in Its Topical Study 2Global Polyvinyl Chloride Demand Is on Upward Trend Now, Says Merchant Research & Consulting in Its Topical Study 3Boston’s Adult Stem Cell Technology Center, LLC Introduces A New Technology for Monitoring Previously Elusive Adult Stem Cells 2Boston’s Adult Stem Cell Technology Center, LLC Introduces A New Technology for Monitoring Previously Elusive Adult Stem Cells 3Boston’s Adult Stem Cell Technology Center, LLC Introduces A New Technology for Monitoring Previously Elusive Adult Stem Cells 4Isis Pharmaceuticals to Present at the Nomura Biotechnology Conference 2Personify's Ryan Carfley Talks Recruiting with Triangle Business Journal, RPG Solutions 2Personify's Ryan Carfley Talks Recruiting with Triangle Business Journal, RPG Solutions 3
... MINNEAPOLIS, Dec. 7, 2011 Uroplasty, Inc. (NASDAQ: ... manufactures and markets innovative proprietary products to treat voiding ... and Medi Jiwani, Vice President and CFO, will present ... Oppenheimer 22nd Annual Healthcare Conference at 2:10 PM ET ...
... IN - Researchers from Purdue and Harvard universities have ... material that could replace silicon and have a 3-D ... approach could enable engineers to build faster, more compact ... less heat than today,s. The transistors contain tiny nanowires ...
... Monsanto , a major biotech corporation ... been given the  Worst Company of 2011 Award ... The award was given by  natural health information ... the worst company of 2011. Numerous ...
Cached Biology Technology:Uroplasty to Present at the Oppenheimer 22nd Annual Healthcare Conference 2New '3-D' transistors promising future chips, lighter laptops 2New '3-D' transistors promising future chips, lighter laptops 3Monsanto Declared Worst Company of 2011 by NaturalSociety 2
(Date:10/29/2014)... released by unconventional oil and gas production are well ... in the open access journal Environmental Health . ... found. The study is the first to be based ... sites and could be used to supplement official air-quality ... reserves that do not readily flow to the surface. ...
(Date:10/29/2014)... and environmental, have been blamed for increasing the ... as a family history of schizophrenia, are widely ... gondii , a parasite transmitted by soil, undercooked ... skepticism. , A new study by Gary Smith, ... University of Pennsylvania,s School of Veterinary Medicine, used ...
(Date:10/29/2014)... – As bodies decompose, their types and numbers ... they provide could mean the difference between a ... State University is using a more than $866,000 ... death-scene investigators examine these changing populations. The microbial ... location of death, gender, race, socioeconomic relations and ...
Breaking Biology News(10 mins):Air quality and unconventional oil and gas sites 2Air quality and unconventional oil and gas sites 3Penn vet professor investigates parasite-schizophrenia connection 2Penn vet professor investigates parasite-schizophrenia connection 3MSU partners with Detroit to investigate death scenes 2
... To gain insights into group dynamics for the study of ... role to play. Enter "Robofish", a computer-controlled replica stickleback that ... of biologists from the University of Leeds in the UK, ... on what motivates fish in a shoal to change direction ...
... of years as an herbal remedy to prevent or treat ... herbal medicines in North America. However, in spite of its ... body,s immune system are conflicting. Now researchers ... are investigating the possibility that Echinacea has other potentially more ...
... The U.S. Food & Drug Administration (FDA) has granted Investigational ... clinical trial evaluating Alpha-1 Antitrypsin (AAT) in type 1 diabetics, ... University of the Negev. This is the first time ... AAT is an FDA-approved off-patent drug currently used to treat ...
Cached Biology News:Fish with chips 2FDA approves trial for type 1 diabetes treatment by Ben-Gurion U. and U. Colorado 2
... a manual heat sealer ideal for low to ... can seal a wide range of plates of ... heating element of the sealer is pre-set for ... seals when used in conjunction with ABgenes sealing ...
... controller is the successor to the original DS-U1. ... of the cameras in the Nikon DS camera ... interface. The DS-U2 transmits information at high speed, ... both hub and mass storage USB 2.0 interfaces. ...
...
This unique buffer provides a gentle method for removal of primary and secondary antibodies to allow several reprobings on the same membrane. Gentle buffer will not alter the antigen for subsequent i...
Biology Products: